

A Single Institution's 26-Year Experience With Nonfunctional Tumors

Annals of Surgery

259, 204-212

DOI: [10.1097/sla.0b013e31828f3174](https://doi.org/10.1097/sla.0b013e31828f3174)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1671-1677.	2.1	148
3	In Reply. <i>Oncologist</i> , 2013, 18, 1240-1241.	1.9	0
4	Lymphadenectomy for Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2014, 259, 213-214.	2.1	9
5	The 2010 WHO Classification of Digestive Neuroendocrine Neoplasms: a Critical Appraisal four years after Its Introduction. <i>Endocrine Pathology</i> , 2014, 25, 186-192.	5.2	141
6	Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 498-511.	1.0	57
7	Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States. <i>Annals of Surgical Oncology</i> , 2014, 21, 3515-3521.	0.7	140
8	Silencing of UCHL1 by CpG Promoter Hyper-methylation is Associated with Metastatic Gastroenteropancreatic Well-Differentiated Neuroendocrine (Carcinoid) Tumors. <i>Annals of Surgical Oncology</i> , 2014, 21, 672-679.	0.7	16
9	Basing Treatment Strategy for Non-functional Pancreatic Neuroendocrine Tumors on Tumor Size. <i>Annals of Surgical Oncology</i> , 2014, 21, 2882-2888.	0.7	69
10	Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems. <i>Medicine (United States)</i> , 2015, 94, e2156.	0.4	43
11	Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. <i>Diagnostics</i> , 2015, 5, 119-176.	1.3	87
12	Classification and Staging of Pancreatic Neuroendocrine Neoplasms. , 2015, , 51-61.		0
14	Pancreatic Neuroendocrine Tumors: an Update. <i>Indian Journal of Surgery</i> , 2015, 77, 395-402.	0.2	15
15	Efficacy and Cost-Effectiveness of Immediate Surgery versus a Wait-and-See Strategy for Sporadic Nonfunctioning T1 Pancreatic Endocrine Neoplasms. <i>Neuroendocrinology</i> , 2015, 101, 25-34.	1.2	10
16	Carcinoid and Neuroendocrine Tumors: Building on Success. <i>Journal of Clinical Oncology</i> , 2015, 33, 1855-1863.	0.8	123
17	Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. <i>European Journal of Cancer</i> , 2015, 51, 1253-1262.	1.3	95
18	Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, hvv143.	0.6	24
19	A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. <i>Nature</i> , 2015, 525, 261-264.	13.7	442
20	A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). <i>Oncotarget</i> , 2016, 7, 24950-24961.	0.8	19

#	ARTICLE	IF	CITATIONS
22	The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. <i>Journal of Clinical Pathology</i> , 2016, 69, 612-618.	1.0	45
23	Surgical Treatment of Non-Functioning Pancreatic Neuroendocrine Tumours Based on Three Clinical Scenarios. <i>Cirug�a Espa�ola (English Edition)</i> , 2016, 94, 578-587.	0.1	0
24	Tratamiento quir�rgico de los tumores neuroendocrinos no funcionantes de p�ncreas basado en 3 escenarios cl�nicos. <i>Cirug�a Espa�ola</i> , 2016, 94, 578-587.	0.1	1
25	Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed Tomography. <i>Pancreas</i> , 2016, 45, 198-203.	0.5	27
26	Prognostic value of Ki-67 in solid pseudopapillary tumor of the pancreas: Huashan experience and systematic review of the literature. <i>Surgery</i> , 2016, 159, 1023-1031.	1.0	67
27	The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2016, 27, 162-170.	5.2	20
28	The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 203-219.	0.4	31
29	Future Prospects in Neuroendocrine Tumor Pathology. , 2016, , 517-523.		0
30	Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors. <i>Medicine (United States)</i> , 2016, 95, e4213.	0.4	10
31	A case of pancreatic neuroendocrine tumors. <i>International Cancer Conference Journal</i> , 2016, 5, 1-4.	0.2	1
32	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. <i>Advances in Medical Sciences</i> , 2016, 61, 147-153.	0.9	45
33	Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States. <i>Medicine (United States)</i> , 2016, 95, e2836.	0.4	23
34	Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. <i>Current Oncology Reports</i> , 2016, 18, 28.	1.8	7
35	Islet Cell Tumors of the Pancreas. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 83-100.	1.0	19
37	Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 193-206.	2.0	21
38	Medical Management of Pancreatic Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 423-437.	0.6	12
39	Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection. <i>Pancreatology</i> , 2016, 16, 397-402.	0.5	12
40	Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 277-283.	0.9	48

#	ARTICLE	IF	CITATIONS
41	Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 103-118.	0.9	32
42	Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors. <i>International Journal of Surgery</i> , 2017, 39, 127-134.	1.1	13
43	Validation and comparison between current prognostication systems for pancreatic neuroendocrine neoplasms: A single-institution experience with 176 patients. <i>Surgery</i> , 2017, 161, 1235-1245.	1.0	15
44	Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 3847-3857.	1.3	26
45	Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors – a systematic review and meta-analysis. <i>Hpb</i> , 2017, 19, 310-320.	0.1	90
46	Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2017, 24, 405-414.	1.6	30
47	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 268-282.	2.0	42
48	Is surgery the best treatment for sporadic small (≤2cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. <i>Pancreatology</i> , 2017, 17, 471-477.	0.5	16
49	Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. <i>British Journal of Cancer</i> , 2017, 117, 1544-1550.	2.9	81
50	Prognostic significance of preoperative gamma-glutamyltransferase to lymphocyte ratio index in nonfunctional pancreatic neuroendocrine tumors after curative resection. <i>Scientific Reports</i> , 2017, 7, 13372.	1.6	16
51	Grade Assignment by Ki-67 Proliferative Index, Mitotic Count, and Phosphohistone H3 Count in Surgically Resected Gastrointestinal and Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 1359-1365.	0.5	6
52	Regional Metastatic Behavior of Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 898-903.	0.5	30
53	Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 600-609.	3.2	164
54	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. <i>Journal of Clinical Oncology</i> , 2017, 35, 274-280.	0.8	124
55	Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors. <i>Medical Science Monitor</i> , 2017, 23, 5574-5588.	0.5	22
56	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2018, 117, 868-878.	0.8	36
57	Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis. <i>Cancer Medicine</i> , 2018, 7, 626-634.	1.3	27
60	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. <i>European Journal of Surgical Oncology</i> , 2018, 44, 778-783.	0.5	49

#	ARTICLE	IF	CITATIONS
61	Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. <i>Cancer Letters</i> , 2018, 412, 188-193.	3.2	42
62	Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. <i>Histopathology</i> , 2018, 72, 168-177.	1.6	75
63	Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors. <i>Surgery</i> , 2018, 163, 226-231.	1.0	9
64	Ki67 Scoring in Pancreatic Neuroendocrine Tumors By a New Method. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 283-287.	0.6	2
65	Surgical resection of pancreatic neuroendocrine neoplasm by minimally invasive surgery—the robotic approach?. <i>Gland Surgery</i> , 2018, 7, 1-11.	0.5	7
66	Les tumeurs neuroendocrines pancréatiques sporadiques: quelle chirurgie pour la tumeur primitive?. <i>Journal De Chirurgie Viscérale</i> , 2018, 155, 497-507.	0.0	0
67	Multiple Machine Learnings Revealed Similar Predictive Accuracy for Prognosis of PNETs from the Surveillance, Epidemiology, and End Result Database. <i>Journal of Cancer</i> , 2018, 9, 3971-3978.	1.2	26
68	Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor. <i>Journal of Visceral Surgery</i> , 2018, 155, 483-492.	0.4	2
69	Lymphadenectomy in pancreatic neuroendocrine neoplasms: Why are we still debating?. <i>Pancreatology</i> , 2018, 18, 855-861.	0.5	8
70	Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: The value of WHO 2010 classification. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2018, 22, 66.	0.1	16
71	Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3928-3935.	0.7	19
72	Role of biomarker tests for diagnosis of neuroendocrine tumours. <i>Nature Reviews Endocrinology</i> , 2018, 14, 656-669.	4.3	84
73	Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms. <i>Kaohsiung Journal of Medical Sciences</i> , 2018, 34, 650-656.	0.8	15
74	Pancreatic Neuroendocrine Tumors (pNETs)., 2018, , 129-157.		0
75	Detección de tumores neuroendocrinos pancreáticos: 23 años de experiencia. <i>Revista De Gastroenterología De México</i> , 2019, 84, 18-25.	0.4	2
76	Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection. <i>Cancer Management and Research</i> , 2019, Volume 11, 7345-7352.	0.9	12
77	Detection of pancreatic neuroendocrine tumors: 23 years of experience. <i>Revista De Gastroenterología De México (English Edition)</i> , 2019, 84, 18-25.	0.1	1
78	Evaluation and Management of Neuroendocrine Tumors of the Pancreas. <i>Surgical Clinics of North America</i> , 2019, 99, 793-814.	0.5	69

#	ARTICLE	IF	CITATIONS
79	Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2019, 26, 2722-2729.	0.7	23
80	Gastroenteropancreatic neuroendocrine tumors: Role of surgery. <i>Annales D'Endocrinologie</i> , 2019, 80, 175-181.	0.6	4
81	A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The "metro-ticket" paradigm. <i>Journal of Surgical Oncology</i> , 2019, 120, 223-230.	0.8	26
82	Predictive value of preoperative MRI features for the Ki-67 index in well-differentiated G1/G2 pancreatic neuroendocrine tumors. <i>Acta Radiologica</i> , 2019, 60, 1394-1404.	0.5	1
83	Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. <i>Pancreatology</i> , 2019, 19, 472-477.	0.5	6
84	Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy: A retrospective cohort study in the SEER database. <i>International Journal of Surgery</i> , 2019, 66, 103-109.	1.1	17
85	The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI. <i>Abdominal Radiology</i> , 2019, 44, 2474-2493.	1.0	8
86	Clinicopathological features and surgical outcomes of resected functional pancreatic neuroendocrine tumors: a single institution experience. <i>Journal of Pancreatology</i> , 2019, 2, 29-34.	0.3	1
87	A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. <i>Journal of Cancer</i> , 2019, 10, 5944-5954.	1.2	33
88	Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2019, 165, 672-685.	1.0	14
89	A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 584-594.	3.2	142
90	Accuracy of grading pancreatic neuroendocrine neoplasms with Ki-67 index in fine-needle aspiration cellblock material. <i>Cytopathology</i> , 2019, 30, 187-193.	0.4	16
91	Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours. <i>Frontline Gastroenterology</i> , 2019, 10, 269-274.	0.9	8
92	The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs). <i>Annals of Surgery</i> , 2019, 269, 725-732.	2.1	50
93	Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study. <i>International Journal of Surgery</i> , 2020, 74, 86-91.	1.1	13
94	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. <i>Hpb</i> , 2020, 22, 1149-1157.	0.1	13
95	Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. <i>European Journal of Radiology</i> , 2020, 122, 108743.	1.2	8
96	Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. , 2020, 8, e001188.		24

#	ARTICLE	IF	CITATIONS
97	A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms. <i>Medicine (United States)</i> , 2020, 99, e22291.	0.4	3
98	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. <i>Surgery</i> , 2020, 168, 816-824.	1.0	4
99	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2021, 111, 728-738.	1.2	13
100	Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 381-386.	0.5	14
101	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. <i>Annals of Surgical Oncology</i> , 2020, 27, 3915-3923.	0.7	2
102	Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis. <i>ESMO Open</i> , 2020, 5, e000632.	2.0	14
103	Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2021, 28, 1614-1624.	0.7	44
104	Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. <i>Future Oncology</i> , 2021, 17, 549-563.	1.1	8
105	Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model. <i>World Journal of Surgery</i> , 2021, 45, 2134-2141.	0.8	2
106	Pancreatic neuroendocrine tumors: Surgical outcomes and survival analysis. <i>American Journal of Surgery</i> , 2021, 221, 529-533.	0.9	7
107	Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 414-422.	0.5	1
108	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. <i>Gut</i> , 2022, 71, 961-973.	6.1	60
109	Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram. <i>Frontiers in Oncology</i> , 2021, 11, 654439.	1.3	7
110	Pathological Evaluation and Classification of Digestive Neuroendocrine Tumours. , 2015, , 59-76.		1
111	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2022, 275, e773-e780.	2.1	13
112	Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. <i>F1000Research</i> , 2017, 6, 663.	0.8	7
113	A single institution's 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factors. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 689-696.	0.1	15
114	Cystic pancreatic neuroendocrine tumors (cPNETs): a systematic review and meta-analysis of case series. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 778-787.	0.1	16

#	ARTICLE	IF	CITATIONS
115	Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system?. <i>Oncotarget</i> , 2017, 8, 82784-82795.	0.8	17
116	Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. <i>Oncotarget</i> , 2019, 10, 6260-6268.	0.8	6
117	Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. <i>World Journal of Gastroenterology</i> , 2015, 21, 9512.	1.4	99
118	Update on pancreatic neuroendocrine tumors. <i>Gland Surgery</i> , 2014, 3, 258-75.	0.5	77
119	Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database. <i>Cancer Research and Treatment</i> , 2019, 51, 1639-1652.	1.3	35
120	Surgical management of pancreatic neuroendocrine neoplasms. <i>Annals of Saudi Medicine</i> , 2014, 34, 1-5.	0.5	7
121	Stage predictivity of neutrophil/lymphocyte and platelet/lymphocyte ratios in pancreatic neuroendocrine tumors. <i>Turkish Journal of Surgery</i> , 2020, 36, 1-8.	0.1	3
122	Diagnosis of Pancreatic Neuroendocrine Tumors. <i>Clinical Endoscopy</i> , 2017, 50, 537-545.	0.6	59
123	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103493.	2.0	4
125	Pancreatic neuroendocrine tumors. Prognostic factors. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 738-739.	0.1	0
126	Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 672.	0.1	0
127	Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. <i>Pancreatology</i> , 2022, 22, 123-129.	0.5	6
128	Pancreas; Endocrine Tumors. , 2020, , 10-23.		0
129	Active surveillance in metastatic pancreatic neuroendocrine tumors: A 20-year single-institutional experience. <i>World Journal of Clinical Cases</i> , 2020, 8, 3751-3762.	0.3	0
131	⁶⁸ Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2352-2363.	3.3	20
132	The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. <i>Human Pathology</i> , 2022, 129, 11-20.	1.1	7
133	Comment on: development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-2.	0.6	0
134	Sporadische nicht-funktionelle pankreatische neuroendokrine Neoplasien. <i>Springer Reference Medizin</i> , 2023, , 463-475.	0.0	0

#	ARTICLE	IF	CITATIONS
135	Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics. <i>Journal of Clinical Medicine</i> , 2022, 11, 7456.	1.0	2
136	Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Human Pathology</i> , 2023, 132, 1-11.	1.1	0
137	Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2023, 15, 2006.	1.7	3